The following specification particularly describes the nature of the invention and the manner in which it is to be performed:

8. The monoclinic form of asenapine maleate  which is stable to micronization  of claim 6 with a powder X-ray diffraction (PXRD) pattern having at least three peaks located at about 9.5  20.3  21.9  23.3  25.1  26.1  26.6  29.0  or 29.9 ? 0.2 degrees 2-theta.
9. The monoclinic form of asenapine maleate  which is stable to micronization  of claim 6 with a powder X-ray diffraction (PXRD) pattern with peaks located substantially as illustrated by Fig.1.
10. The monoclinic form of asenapine maleate  which is stable to micronization  of claim 6 with any one or more of a powder X-ray diffraction (PXRD) pattern  a differential scanning calorimetry (DSC) curve  and a thermogravimetric analysis (TGA) curve  substantially as illustrated by Figs. 1  3  and 4  respectively.
11. A process for the preparation of the monoclinic form of asenapine maleate  which is stable to micronization  of any one of claims 7 to 10  comprising:
a) providing a solution of asenapine in a solvent;
b) combining the solution of asenapine prepared in step a) with a solution of maleic acid in a solvent; and
c) isolating the monoclinic form of asenapine maleate.
12 A process for the preparation of the monoclinic form of asenapine maleate  which is stable to micronization  of any one of claims 7 to 10  comprising:
a) providing a solution of asenapine maleate in a solvent;
b) optionally  seeding the solution prepared in step a with crystals of the monoclinic form; and
c) isolating the monoclinic form of asenapine maleate.